The medical community uses several FDA-approved peptides to treat specific conditions because they have undergone years of rigorous testing to prove they are both safe and effective
A 2018 attempt by an independent lab to reproduce the headline neurotrophic effect in vitro reportedly produced mixed results, which is a typical finding when independent groups try to replicate striking preclinical findings
Common Side Effects Unknown human profile: Because human trials were never completed, adverse-event rates, immunogenicity and long-term risks for either peptide are simply uncharacterised
nausea decreases with ongoing usage a steady weight loss occurs in some patients over 2 years (may be related to nausea & CNS-mediated loss of appetite) there is an increased risk of hypoglycemia when exenatide is used with a sulfonylurea The dose of the sulfonylurea may need to be reduced if hypoglycemia occurs when combined with exenatide Most serious : rare & sometimes fatal necrotizing or hemorrhagic pancreatitis When initiating patients on Byetta, watch for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting)
Hypothalamic-pituitary-adrenal hypofunction in myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) as a consequence of activated immune-inflammatory and oxidative and nitrosative pathways
